Skip to main content
main-content

Medications

Highlights

03-18-2019 | Dapagliflozin | Highlight | News

DECLARE analyses show dapagliflozin benefits for reduced ejection fraction, prior MI subgroups

Further analysis of the DECLARE-TIMI 58 trial shows dapagliflozin to be of particular benefit for patients who have previous myocardial infarction or heart failure with reduced ejection fraction.

03-12-2019 | Medications | DUKPC 2019 | News

Adding second diabetes medication better than switching in face of poor response

Adding an additional glucose-lowering medication is better than switching to a different one in people with type 2 diabetes, even if the original seemed to have little or no effect, shows an analysis from the MASTERMIND consortium.

02-25-2019 | Devices and technology | Highlight | News

d-Nav system helps people with type 2 diabetes optimize insulin doses

The d-Nav system, which calculates insulin dose adjustments according to glucose levels, can help people with type 2 diabetes achieve larger reductions in glycated hemoglobin levels than with healthcare professional support alone, shows a randomized trial in The Lancet.

02-19-2019 | Artificial pancreas systems | Feature | Article

What’s all the fuss about the DIY artificial pancreas?

DIY closed-loop insulin delivery has provoked controversy within the diabetes community, raising questions around patient empowerment, safety and liability, and whether the regulatory process remains fit for purpose in a technological age. medwireNews takes a look at the issues.

02-12-2019 | SGLT2 inhibitors | Highlight | News

Recommendations issued for managing SGLT inhibitor-associated DKA risk in type 1 diabetes

Experts have developed consensus recommendations for minimizing diabetic ketoacidosis risk in patients with type 1 diabetes treated with SGLT inhibitors.

01-17-2019 | Glucokinase activators | Highlight | News

Hepatic glucokinase activation may improve glycemic control in type 2 diabetes

The hepatoselective glucokinase activator TTP399 reduces glycated hemoglobin levels without increasing the risk for hypoglycemia among patients with type 2 diabetes, suggest findings from the phase IIb AGATA trial.

01-02-2019 | Canagliflozin | medwireNews | News

No fracture risk found with canagliflozin in real-world data

Research based on insurance claims data indicates that new users of the sodium-glucose cotransporter-2 inhibitor canagliflozin are no more likely to experience a fracture than new users of glucagon-like peptide-1 receptor agonists.

12-19-2018 | Insulin degludec | Highlight | News

Real-world data show benefits of insulin degludec vs glargine in type 2 diabetes

Insulin-naive adults with type 2 diabetes derive greater benefit from treatment with insulin degludec than from insulin glargine 300 units/mL, results from the US clinical practice-based CONFIRM study show.

12-07-2018 | DPP-4 inhibitors | medwireNews | News

Possible bile duct cancer risk with incretin-based medications

Data from clinical practice suggest the possibility of an increased relative risk for cholangiocarcinoma among patients taking incretin-based antidiabetes medications, although the absolute risk remains small.

12-03-2018 | Liraglutide (T2DM) | medwireNews | News

Older type 2 diabetes patients may derive greatest liraglutide benefits

The LEADER investigators report that treatment with the glucagon-like peptide-1 receptor agonist liraglutide may be of particular benefit in the oldest patients with type 2 diabetes.

11-20-2018 | Insulin | Highlight | News

Research predicts ‘highly inadequate’ insulin access in coming years

A modeling study predicts a greater than 20% increased need for insulin to treat patients with type 2 diabetes over the next 22 years, with implications for medication access.

11-10-2018 | Dapagliflozin | Highlight | News

DECLARE-TIMI 58 supports CV benefits of SGLT2 inhibitor class

The results of the DECLARE-TIMI 58 trial show a broadly positive effect of dapagliflozin on cardiovascular outcomes, especially heart failure, in patients with type 2 diabetes.

11-06-2018 | Cardiovascular outcomes | Highlight | News

Type 2 diabetes, polyvascular disease combine to increase cardiovascular risk

Type 2 diabetes and polyvascular disease are additive risk factors for cardiovascular events in patients with acute coronary syndromes, a secondary analysis of the IMPROVE-IT trial suggests.

10-22-2018 | Mental health | Highlight | News

Insulin manipulation strongly linked to psychiatric comorbidity

Insulin manipulation, the practice of deliberately under- or overdosing insulin, is strongly associated with psychiatric comorbidity in children and young adults with type 1 diabetes, Austrian research shows.

10-04-2018 | Empagliflozin | EASD 2018 | News

EASE: Add-on empagliflozin improves glycemic control in type 1 diabetes

The addition of empagliflozin to insulin therapy reduces glycated hemoglobin levels in patients with type 1 diabetes, indicate findings from the phase III EASE-2 and 3 trials.

10-04-2018 | GLP-1 agonists | EASD 2018 | News

Promising phase II data for dual GIP and GLP-1 receptor agonist

A compound that stimulates the receptors for both glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 has dose-dependent effects on glucose levels and bodyweight in people with type 2 diabetes.

10-03-2018 | Lixisenatide | EASD 2018 | News

Lixisenatide may lessen albuminuria progression in type 2 diabetes

Macroalbuminuric patients with type 2 diabetes and a recent acute coronary event who are treated with lixisenatide may experience a reduction in their urinary albumin-to-creatinine ratio, suggests an exploratory post-hoc analysis of the ELIXA trial.

10-02-2018 | Albiglutide | EASD 2018 | News

Albiglutide reduces cardiovascular risk in patients with type 2 diabetes

Results of the Harmony Outcomes trial indicate that adding the glucagon-like peptide-1 receptor agonist albiglutide to standard care may reduce cardiovascular risk among patients with type 2 diabetes and existing cardiovascular disease.

09-30-2018 | UKPDS | Feature | Article

The UKPDS: A lasting legacy

Twenty years after the publication of the primary findings, medwireNews talks to longtime UKPDS investigator Professor David Matthews (University of Oxford, UK) about the struggles of the team to bring the trial to completion and the impact of the findings on diabetes care.

09-18-2018 | Sexual dysfunction | View from the clinic | Article

Regaining sexual health in diabetes: Start with open communication

Advisory Board member Clipper Young recounts an experience of starting a patient with erectile dysfunction on the path to appropriate treatment for him and his diabetes.

image credits